Improved Signs and Symptoms of Dry Eye Disease for Restasis ® Patients Following a Single Tearcare ® Treatment: Phase 2 of the SAHARA Study.
Brandon D AyresMarc R BloomensteinJennifer LohThomas ChesterBobby SaenzJulio EchegoyenShane R KannarrTomasita C RodriguezJaime E DickersonPublished in: Clinical ophthalmology (Auckland, N.Z.) (2024)
SAHARA showed 6-month superiority of LHT to CsA in clinical signs and non-inferiority in symptom scores. This extension shows that patients treated with CsA for 6 months can achieve meaningful additional improvement in signs and symptoms lasting for as long as 6 months following a single LHT treatment without the need for topical prescription therapy.